Literature DB >> 10758273

Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps.

M Adler1, B Capacio, S S Deshpande.   

Abstract

The ability of 3,4-diaminopyridine (3,4-DAP) to antagonize muscle paralysis following local injection of botulinum neurotoxin A (BoNT/A) complex was evaluated in the in situ rat extensor digitorum longus (EDL) preparation. The minipumps were implanted 6 h prior to BoNT/A administration and delivered their contents over a 7-day period producing a steady plasma 3,4-DAP concentration of 27-29 microM. In the absence of 3,4-DAP, a local injection of five mouse LD(50) units of BoNT/A led to total paralysis of EDL muscles within 24 h of application. Recovery from paralysis was slow, remaining at <30% of control 14 days after toxin injection. 3,4-DAP delivery by osmotic minipumps antagonized the actions of BoNT/A on neuromuscular transmission. Seven days after the onset of 3,4-DAP infusion, indirectly elicited twitch and tetanic tensions in BoNT/A-injected EDL muscles were 72.4 and 46.9% of control, respectively. In the absence of 3,4-DAP, twitch and tetanic tensions were only 5.4 and 15. 1% of control. The benefits conferred by 3,4-DAP treatment were not maintained after minipumps were removed. Seven days after cessation of 3,4-DAP infusion, twitch and tetanic tensions were not significantly different from those observed in muscles receiving BoNT/A alone. It is concluded that 3,4-DAP may be useful for treatment of BoNT/A-induced muscle paralysis, but sustained delivery of the drug would be required for the entire period of BoNT intoxication to maintain muscle function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10758273     DOI: 10.1016/s0041-0101(99)00231-7

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  9 in total

1.  An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists.

Authors:  Lisa M Eubanks; Mark S Hixon; Wei Jin; Sukwon Hong; Colin M Clancy; William H Tepp; Michael R Baldwin; Carl J Malizio; Michael C Goodnough; Joseph T Barbieri; Eric A Johnson; Dale L Boger; Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-09       Impact factor: 11.205

2.  Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication.

Authors:  T L Harris; C J Wenthur; A Diego-Taboada; G Mackenzie; T S Corbitt; K D Janda
Journal:  Chem Commun (Camb)       Date:  2016-03-18       Impact factor: 6.222

3.  Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions.

Authors:  Baskaran Thyagarajan; Joseph G Potian; Carmen C Garcia; Kormakur Hognason; Katerina Capková; Scott T Moe; Alan R Jacobson; Kim D Janda; Joseph J McArdle
Journal:  Neuropharmacology       Date:  2010-03-06       Impact factor: 5.250

4.  Symptomatic treatment of botulism with a clinically approved small molecule.

Authors:  Edwin Vazquez-Cintron; James Machamer; Celinia Ondeck; Kathleen Pagarigan; Brittany Winner; Paige Bodner; Kyle Kelly; M Ross Pennington; Patrick McNutt
Journal:  JCI Insight       Date:  2020-01-30

5.  Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization.

Authors:  Joseph S Zakhari; Isao Kinoyama; Mark S Hixon; Antonia Di Mola; Daniel Globisch; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2011-09-14       Impact factor: 3.641

6.  A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity.

Authors:  Tyler L Harris; Colin A Lowery; Mark S Hixon; Kim D Janda
Journal:  ACS Chem Neurosci       Date:  2014-07-11       Impact factor: 4.418

7.  3,4-Diaminopyridine may improve neuromuscular block during botulism.

Authors:  Arnaud Friggeri; Frédéric Marçon; Sandra Marciniak; Anne-Sophie Lemaire-Hurtel; Abdoul Seydi; Nacim Ammenouche; Mélanie Levrard; Yazine Mahjoub; Norik Airapetian; François Tinturier; Michel Petitjean; Hervé Dupont
Journal:  Crit Care       Date:  2013-09-05       Impact factor: 9.097

8.  Cleavage of SNAP25 and its shorter versions by the protease domain of serotype A botulinum neurotoxin.

Authors:  Rahman M Mizanur; Robert G Stafford; S Ashraf Ahmed
Journal:  PLoS One       Date:  2014-04-25       Impact factor: 3.240

9.  The Necessity of a Locally Active Antidote in the Clinical Practice of Botulinum Neurotoxin Therapy: Short Communication.

Authors:  Harald Hefter; Sara Samadzadeh
Journal:  Medicina (Kaunas)       Date:  2022-07-14       Impact factor: 2.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.